NEW YORK (GenomeWeb News) – Patients of Asian ancestry taking the drug carbamazepine will now be advised to take a genetic test to determine whether they have a heightened risk of developing a rare but serious skin reaction, the US Food and Drug Administration said in a statement today. 
 
Carbamazepine treats epilepsy, bipolar disorder, and neuropathic pain, and is sold under the brand names Carbatrol, Equetro, and Tegretol by Shire Pharmaceuticals, Validus Pharmaceuticals, and Novartis, respectively.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.